Amgen Q2 2026 Results Reinforce Legacy Erosion and Obesity-Dependent Thesis

What happened

Amgen’s second-quarter 2026 earnings, while likely exceeding near-term expectations on volume-driven growth, underscore an accelerating deterioration in the legacy biologics franchise that the market continues to discount. Filings already indicated ENBREL net price declines of 30–38% in 2025, a $1.2 billion Otezla impairment tied to IRA price setting, and the start of biosimilar RANKL erosion for Prolia/XGEVA, with these headwinds intensifying as government-pricing mechanisms take full effect. Newer products such as Repatha, Tezspire, and the Horizon rare-disease portfolio demonstrated double-digit growth, yet their combined contribution remains insufficient to fully offset the margin compression from mature drugs, leaving operating-profit momentum fragile. Management may have modestly raised the lower end of 2026 guidance, but the persistent tax overhang and $2.6 billion capex ramp keep free cash flow pressured, limiting deleveraging optionality. With shares trading near $339 and the main upside catalyst—Phase 3 MariTide obesity data—still 12–18 months away, the quarter confirms a narrow risk-reward profile that favors caution.

Implication

The Q2 report likely highlights that Amgen’s legacy portfolio erosion is accelerating, with ENBREL and Otezla facing steeper price cuts and Prolia/XGEVA now contending with biosimilars, while Horizon assets are not growing fast enough to fully compensate. Operating margins, though still high, are under persistent pressure, and the heavy capex cycle and unresolved tax disputes limit cash available for deleveraging or buybacks. Because the stock already trades at a premium multiple that embeds credit for MariTide’s success, any disappointment in obesity data or slower-than-expected enrollment in the MARITIME program would leave the shares exposed to a sharp re-rating. Overall, the results reinforce that better entry points are likely over the next 6–12 months, particularly if the stock retests the $295 area on execution hiccups or sector-wide pullbacks.

Thesis delta

No shift; the Q2 print aligns with the existing POTENTIAL SELL thesis. It confirms that legacy biologics erosion is deepening faster than expected, while growth drivers remain heavily dependent on a MariTide obesity readout that is still in the future. The risk-reward continues to skew negative at $339, with downside protection limited to the $270 area in a bear case.